MetaCap

Candel Therapeutics (CADL) vs Tectonic Therapeutic (TECX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Candel Therapeutics (CADL) has outperformed Tectonic Therapeutic (TECX) over the past year, gaining 10.8% versus a gain of 8.1%. Over five years, CADL leads with a -48.5% price change compared with -57.7% for TECX. Tectonic Therapeutic is the larger company by market cap ($405.3 million vs $395.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CADL+10.77%TECX+8.08%
+213%+98%-17%
Nov 21, 20251 yearNov 20, 2026
CADL-53.63%TECX-59.45%
+27%-38%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CADL versus TECX key metrics
MetricCADLTECX
Share price$5.04$20.73
Market cap$395.37M$405.26M
1-day change-1.75%-1.47%
YTD return-10.80%-0.62%
1-year return+10.77%+8.08%
5-year return-48.47%-57.66%
EPS (TTM)$-1.53$-4.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-38.18M$-74.15M
52-week high$14.00$39.53
52-week low$4.35$16.77
Distance from 52-week high-64.00%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+250.60%+242.50%
Average volume1.26M212.16K
Shares outstanding78.45M19.55M
Employees5560
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

About Tectonic Therapeutic

TECX stock →

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

CADL vs TECX FAQ

Which is bigger, Candel Therapeutics or Tectonic Therapeutic?

Tectonic Therapeutic (TECX) is larger, with a market capitalization of $405.26M compared with $395.37M for Candel Therapeutics (CADL).

Which stock has performed better over the past year, CADL or TECX?

CADL returned +10.77% over the past 12 months, compared with +8.08% for TECX (price return, excluding dividends). Past performance does not predict future results.

Are Candel Therapeutics and Tectonic Therapeutic in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons